MCC950 Sodium: Selective NLRP3 Inflammasome Inhibition in Macrophages

Executive Summary: MCC950 sodium (B7946, APExBIO) is a potent and highly selective small-molecule inhibitor of the NLRP3 inflammasome, with an IC₅₀ of 7.5 nM in murine BMDMs and comparable activity in human macrophages (APExBIO product page). It blocks both canonical and noncanonical NLRP3 activation without affecting AIM2, NLRC4, or NLRP1 inflammasomes, offering specificity for inflammasome pathway studies (Yuan et al., 2022). MCC950 sodium is highly water-soluble (≥124 mg/mL) and used in preclinical models of autoimmune and inflammatory diseases. It dose-dependently inhibits IL-1β release in BMDMs, HMDMs, and PBMCs, without interfering with TNF-α secretion. In vivo, MCC950 sodium reduces serum IL-1β and IL-6 after LPS challenge and attenuates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.

Biological Rationale

The NLRP3 inflammasome is a cytosolic protein complex central to innate immune activation and inflammatory signaling. Its activation leads to caspase-1 cleavage, gasdermin D pore formation, and the release of pro-inflammatory cytokines IL-1β and IL-18 (Yuan et al., 2022). Dysregulated NLRP3 activity is implicated in atherosclerosis, autoinflammatory syndromes, and neuroinflammatory disorders. Selective inhibition of NLRP3 is critical for dissecting disease mechanisms—especially pyroptosis, a form of programmed cell death distinct from apoptosis and necrosis (related article). MCC950 sodium enables precise blockade of NLRP3-dependent inflammation without broadly suppressing immune function or affecting other inflammasomes, which distinguishes it from less selective anti-inflammatory agents (e.g., curcumin or pan-caspase inhibitors).

Mechanism of Action of MCC950 sodium

MCC950 sodium (also known as CRID3 sodium salt) directly inhibits the NLRP3 inflammasome by binding to the Walker B motif in the NACHT domain, preventing ATP hydrolysis and oligomerization necessary for complex assembly (see mechanistic review). This selectivity is not observed for AIM2, NLRC4, or NLRP1, which possess distinct structural domains and activation requirements. MCC950 sodium blocks both canonical (e.g., K⁺ efflux, nigericin) and noncanonical (e.g., caspase-11 activation) pathways, thereby halting downstream caspase-1 activation, pyroptosis, and mature IL-1β/IL-18 secretion. Its specificity is validated by the absence of effect on TNF-α release and viability in unrelated cell types at working concentrations (10 μM, 2 h, 37°C, RPMI-1640 medium) (Yuan et al., 2022).

Evidence & Benchmarks

• MCC950 sodium inhibits NLRP3 inflammasome activation in murine BMDMs with an IC₅₀ of 7.5 nM (APExBIO datasheet, product page).
• Comparable potency is observed in human monocyte-derived macrophages (HMDMs), supporting cross-species utility (Yuan et al., 2022).
• Blocks both canonical (K⁺ efflux, nigericin) and noncanonical (caspase-11) NLRP3 activation, but not AIM2, NLRC4, or NLRP1 inflammasomes (review article).
• Inhibits IL-1β release in BMDMs, HMDMs, and PBMCs without affecting TNF-α secretion, indicating pathway specificity (Yuan et al., 2022).
• In vivo, intraperitoneal MCC950 sodium (dose and schedule per model) significantly reduces serum IL-1β and IL-6 after LPS challenge and attenuates experimental autoimmune encephalomyelitis severity in mice (Yuan et al., 2022).
• Highly soluble: ≥124 mg/mL in water, ≥21.45 mg/mL in DMSO, ≥43 mg/mL in ethanol (APExBIO datasheet, product page).
• Recommended storage: -20°C; avoid long-term storage of solutions to maintain stability (APExBIO).

This article updates and extends the discussion in 'MCC950 Sodium: Transforming NLRP3 Inflammasome Research' by providing new quantitative benchmarks and clarifying selectivity boundaries. For a translational perspective, see also 'MCC950 Sodium: Transforming Translational Research in NLRP3', which focuses on bridging preclinical and clinical applications; this article details more mechanistic and workflow-specific considerations. For a focused discussion on mechanistic insights and translational evidence, consult 'Decoding NLRP3 Inflammasome Inhibition'.

Applications, Limits & Misconceptions

MCC950 sodium is a critical reagent for:

• Dissecting NLRP3-dependent inflammatory signaling in cellular models (macrophages, PBMCs, HUVECs).
• Validating NLRP3 involvement in animal models of autoimmune and inflammatory diseases (e.g., multiple sclerosis, atherosclerosis).
• Screening candidate therapeutics that modulate inflammasome signaling.
• Distinguishing between canonical and noncanonical NLRP3 activation mechanisms.

Common Pitfalls or Misconceptions

• MCC950 sodium does not inhibit non-NLRP3 inflammasomes (AIM2, NLRC4, NLRP1).
• It is not a general anti-inflammatory or antioxidant; specificity is restricted to NLRP3 pathways.
• Long-term storage of solutions at room temperature leads to compound degradation.
• High concentrations may exert off-target effects; empirical titration is essential.
• Not suitable for direct clinical use; it is a research reagent only.

Workflow Integration & Parameters

The recommended working concentration for MCC950 sodium in cell-based assays is 10 μM, with pre-incubation of 2 h at 37°C. Solubilize in water, DMSO, or ethanol according to downstream compatibility (≥124 mg/mL in water). For animal models, dosing regimens depend on disease context and must be optimized for pharmacokinetics and toxicity. Store powder at -20°C and avoid repeated freeze-thaw cycles. The compound is available from APExBIO as B7946 (product page).

Conclusion & Outlook

MCC950 sodium is the gold-standard selective NLRP3 inflammasome inhibitor for mechanistic and translational research. Its nanomolar potency, pathway specificity, and cross-species utility enable robust investigation of NLRP3-driven pathology in vitro and in vivo. As diseases such as atherosclerosis, multiple sclerosis, and other NLRP3-associated inflammatory conditions are better understood, MCC950 sodium will remain a foundational tool for preclinical discovery and validation. For comprehensive application and mechanistic details, refer to the MCC950 sodium product page and recent literature (Yuan et al., 2022).